Eric Burak

Eric Burak has more than 20 years of pharmaceutical research and development experience in both biotech and large pharmaceutical companies. Before joining Fusion, he was Vice President of Development at Theracos Inc., where he was responsible for all research, clinical development and manufacturing activities for a company developing drugs to treat Type 2 diabetes. Previous positions include Vice President of Preclinical and Early Clinical Development at Rib-X Pharmaceuticals, Inc., a venture-funded antibiotic company, and Director of Drug Metabolism and Pharmacokinetics at Guilford Pharmaceuticals, Inc.

Eric Burak’s industrial experience has focused on integrating discovery and development processes to accelerate identification and development of new therapeutic agents. He has submitted 14 Investigational New Drug Applications (INDs) and has developed 2 approved products across multiple therapeutic areas including oncology, cardiovascular, antibiotics, diseases of the central and peripheral nervous system, anesthesia/sedation, diabetes, and wound healing.

Eric Burak holds a PhD in Analytical Chemistry from Temple University and a BSc in Chemistry from Drexel University.

Eric Burak is the Chief Scientific Officer at Fusion Pharmaceuticals, based in North America. With a background in Biotechnology, Eric Burak has a rich history of leadership and innovation.Eric Burak studied PhD Analytical Chemistry at Temple University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.